Experienced in Angiosarcoma

Jens T. Siveke

Bridge Institute Of Experimental Tumor Therapy And Division Of Solid Tumor Translational Oncology, 
Essen, NW, DE 
Experienced in Angiosarcoma
Bridge Institute Of Experimental Tumor Therapy And Division Of Solid Tumor Translational Oncology, 
Essen, NW, DE 
OverviewLocationsClinical Research

Overview

Jens Siveke practices in Essen, Germany. Mr. Siveke is rated as an Experienced expert by MediFind in the treatment of Angiosarcoma. His top areas of expertise are Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Solitary Fibrous Tumor, Pancreaticoduodenectomy, and Hepato-Pancreato-Biliary Surgery.

His clinical research consists of co-authoring 240 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Angiosarcoma.

Gender
Male

Locations

Bridge Institute Of Experimental Tumor Therapy And Division Of Solid Tumor Translational Oncology, Essen, NW, Germany
Other Locations
Heidelberg, BW, Germany
Munich, BY, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase Ib/II Single-arm Study Evaluating the Safety and Efficacy of Combined Immunotherapy With mFOLFOX6, Bevacizumab and Atezolizumab in Advanced-stage Biliary Tract Cancer
A Phase Ib/II Single-arm Study Evaluating the Safety and Efficacy of Combined Immunotherapy With mFOLFOX6, Bevacizumab and Atezolizumab in Advanced-stage Biliary Tract Cancer
Enrollment Status: Completed
Publish Date: September 29, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Biological, Drug
Study Drugs: IMCgp100, Dacarbazine, Ipilimumab, Pembrolizumab
Study Phase: Phase 2
Minimizing the Risk of Metachronous Adenomas of the Colorectum With Green Tea Extract -MIRACLE-
Minimizing the Risk of Metachronous Adenomas of the Colorectum With Green Tea Extract -MIRACLE-
Enrollment Status: Completed
Publish Date: September 20, 2019
Intervention Type: Dietary supplement
Study Phase: Phase 2
View 2 Less Clinical Trials

240 Total Publications

Leveraging Sarcopenia index by automated CT body composition analysis for pan cancer prognostic stratification.
Leveraging Sarcopenia index by automated CT body composition analysis for pan cancer prognostic stratification.
Journal: NPJ digital medicine
Published: August 09, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Siveke's expertise for a condition
ConditionClose
View All 33 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile